CLINICAL TRIALS PROFILE FOR BENDEKA

All Clinical Trials for BENDEKA

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01286272 ↗	Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma	Active, not recruiting	National Cancer Institute (NCI)	Phase 2	2011-04-08	This randomized phase II trial studies how well ofatumumab and bendamustine hydrochloride with or without bortezomib works in treating patients with untreated follicular non-Hodgkin lymphoma. Monoclonal antibodies, such as ofatumumab, may block cancer growth in different ways by targeting certain cells. Drugs used in chemotherapy, such as bendamustine hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Bortezomib may also stop the growth of cancer cells by blocking blood flow to the tumor. It is not yet known whether ofatumumab and bendamustine hydrochloride are more effective with bortezomib in treating patients with follicular non-Hodgkin lymphoma.
NCT01754402 ↗	Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma	Active, not recruiting	Celgene	Phase 1/Phase 2	2013-01-07	This study is designed as a phase I-II, open label, dose finding study. Study treatment will be as follows, in 28 day cycles: - Pomalidomide: once daily orally (PO) dosing on days 1-21, every 28 days - Bendamustine: once intravenously (IV) dosing on day 1, every 28 days - Dexamethasone: weekly PO or IV dosing on days 1, 8, 15, and 22. After completing 6 cycles of treatment, dexamethasone may be decreased to 20mg per investigator discretion. After completing 12 cycles of treatment, patients will proceed to the maintenance phase of the study. Patients will receive Pomalidomide on day 1-21, every 28 days and dexamethasone on days 1, 8, 15, and 22 every 28 days until time of progression.
NCT01754402 ↗	Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma	Active, not recruiting	Cristina Gasparetto	Phase 1/Phase 2	2013-01-07	This study is designed as a phase I-II, open label, dose finding study. Study treatment will be as follows, in 28 day cycles: - Pomalidomide: once daily orally (PO) dosing on days 1-21, every 28 days - Bendamustine: once intravenously (IV) dosing on day 1, every 28 days - Dexamethasone: weekly PO or IV dosing on days 1, 8, 15, and 22. After completing 6 cycles of treatment, dexamethasone may be decreased to 20mg per investigator discretion. After completing 12 cycles of treatment, patients will proceed to the maintenance phase of the study. Patients will receive Pomalidomide on day 1-21, every 28 days and dexamethasone on days 1, 8, 15, and 22 every 28 days until time of progression.
NCT01886872 ↗	Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia	Active, not recruiting	National Cancer Institute (NCI)	Phase 3	2013-12-09	This randomized phase III trial studies rituximab with bendamustine hydrochloride or ibrutinib to see how well they work compared to ibrutinib alone in treating older patients with previously untreated chronic lymphocytic leukemia. Monoclonal antibodies, such as rituximab, may block cancer growth in different ways by targeting certain cells. Drugs used in chemotherapy, such as bendamustine hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It is not yet known whether rituximab with bendamustine hydrochloride may work better than rituximab and ibrutinib or ibrutinib alone in treating chronic lymphocytic leukemia.
NCT02153580 ↗	Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia	Active, not recruiting	National Cancer Institute (NCI)	Phase 1	2014-09-24	This phase I trial studies the side effects and best dose of cellular immunotherapy following chemotherapy in treating patients with non-Hodgkin lymphomas, chronic lymphocytic leukemia, or B-cell prolymphocytic leukemia that has come back. Placing a modified gene into white blood cells may help the body build an immune response to kill cancer cells.
NCT02153580 ↗	Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia	Active, not recruiting	City of Hope Medical Center	Phase 1	2014-09-24	This phase I trial studies the side effects and best dose of cellular immunotherapy following chemotherapy in treating patients with non-Hodgkin lymphomas, chronic lymphocytic leukemia, or B-cell prolymphocytic leukemia that has come back. Placing a modified gene into white blood cells may help the body build an immune response to kill cancer cells.
NCT02972840 ↗	A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL	Recruiting	Acerta Pharma BV	Phase 3	2017-04-05	This study is evaluating the efficacy of acalabrutinib in combination with bendamustine and rituximab (BR) compared with placebo plus BR in subjects with previously untreated mantle cell lymphoma.

Clinical Trial Conditions for BENDEKA

Condition Name

Condition Name for BENDEKA
Intervention	Trials
Recurrent Follicular Lymphoma	3
Mantle Cell Lymphoma	3
Grade 3a Follicular Lymphoma	2
Refractory Follicular Lymphoma	2

Condition MeSH

Condition MeSH for BENDEKA
Intervention	Trials
Lymphoma	15
Leukemia, Lymphoid	5
Leukemia, Lymphocytic, Chronic, B-Cell	5
Lymphoma, Mantle-Cell	5

Clinical Trial Locations for BENDEKA

Trials by Country

Trials by Country for BENDEKA
Location	Trials
United States	189
Canada	8
Germany	2
Korea, Republic of	1
Australia	1

Trials by US State

Trials by US State for BENDEKA
Location	Trials
North Carolina	9
California	8
Texas	8
Missouri	8
South Carolina	6

Clinical Trial Progress for BENDEKA

Clinical Trial Phase

Clinical Trial Phase for BENDEKA
Clinical Trial Phase	Trials
Phase 3	4
Phase 2	10
Phase 1/Phase 2	4

Clinical Trial Status

Clinical Trial Status for BENDEKA
Clinical Trial Phase	Trials
Recruiting	11
Active, not recruiting	6
Not yet recruiting	3

Clinical Trial Sponsors for BENDEKA

Sponsor Name

Sponsor Name for BENDEKA
Sponsor	Trials
National Cancer Institute (NCI)	9
Acerta Pharma BV	2
Washington University School of Medicine	2

Sponsor Type

Sponsor Type for BENDEKA
Sponsor	Trials
Other	16
Industry	14
NIH	9

BENDEKA (bendamustine) Clinical Trials Update, Market Analysis, and Revenue Projection

Last updated: July 26, 2026

BENDEKA (bendamustine hydrochloride) is a branded oncology product whose market opportunity is driven by the cadence of new clinical placements in indolent non-Hodgkin lymphoma (iNHL) and multiple myeloma (post–transplant settings) where bendamustine-based regimens remain common, and by the competitive pressure from established generics of bendamustine. Revenue projections for BENDEKA depend primarily on (1) share loss to authorized and non-authorized generics, (2) payer and hospital formulary dynamics, and (3) any clinically meaningful positioning in current standards for iNHL.

What clinical trials update exists for BENDEKA (bendamustine) in 2024–2026?

Clinical activity in bendamustine broadly centers on optimizing combination regimens (anti-CD20 backbones, BTK inhibitors, BCL2/HSP90 axes, and post–CAR-T/HSCT sequencing) and improving tolerability in iNHL and related B-cell malignancies. Trial readouts most relevant to BENDEKA’s label use cases typically evaluate bendamustine-containing schedules rather than BENDEKA-specific branded formulation endpoints, so the practical impact is on prescribing behavior for bendamustine as a class.

Which indications are most active for bendamustine-based regimens?

Featured clinical interest by category:

• iNHL (follicular lymphoma, marginal zone lymphoma, lymphoplasmacytic lymphoma) using bendamustine plus rituximab or obinutuzumab analogs and subsequent lines.
• Multiple myeloma in settings where bendamustine is used in combination strategies, including post–transplant consolidation/maintenance strategies in some protocols.
• Relapsed/refractory B-cell malignancies where combination selection seeks to reduce progression while managing myelosuppression and infusion reactions.

What endpoints most affect real-world adoption of bendamustine combinations?

Across recent bendamustine combination studies, the uptake lever is usually:

• Progression-free survival and response durability in relapsed settings
• Safety profile shifts (neutropenia, infection rates, infusion reactions)
• Feasibility of schedule delivery (cycle-to-cycle dose modifications, outpatient administration compatibility)

How should investors and competitors interpret “bendamustine” trial readouts for BENDEKA specifically?

Trial readouts that validate bendamustine-based efficacy shift prescribing toward bendamustine class regimens. But BENDEKA’s ability to monetize depends on whether payers steer to lowest-acquisition-cost generics versus retaining branded spend. That dynamic often dominates clinical evidence in determining net revenue.

What is the FDA status and Orange Book listing for BENDEKA (bendamustine)?

BENDEKA is an approved bendamustine hydrochloride product. The monetization floor is tied to whether FDA-approved alternatives have generic substitution and to how Orange Book listed patents (drug substance and formulation) affect generic launch timing in relevant strengths/dosage forms.

What Orange Book risks exist for BENDEKA?

Key generic-entry pathways affecting BENDEKA:

• ANDA paragraph IV challenges to Orange Book-listed patents for bendamustine drug products or associated formulation/method patents
• 505(b)(2) or switch-to-generic dynamics where dosing schedules, stability, or administration instructions are deemed equivalent for substitutability

What does market practice suggest about exclusivity?

In most mature oncology small-molecule spaces, branded products with long-standing use typically face:

• Loss of differentiated share once generic supply expands
• Residual brand pull mainly in institutions with established purchasing contracts or limited bid depth

How strong is the patent estate for BENDEKA (bendamustine) and what patents matter?

For BENDEKA specifically, the patent strength question is usually answered by Orange Book coverage mapping: (1) drug substance and salt form, (2) formulation, (3) manufacturing process, and (4) method of use if any are listed.

What patent categories typically control BENDEKA-like oncology brands?

• Drug substance composition/polymorph or salt (usually long ago filed, often expired or near-expiry for older actives)
• Drug product formulation (stabilizers, lyophilization/solution handling, container-closure system)
• Manufacturing process (critical steps and impurity profiles)
• Method-of-use claims tied to dosing schedules or combination regimens (often less frequently decisive in generic entry because labeling and proof-of-use carve-outs can weaken enforcement)

How does patent strength translate to generic entry risk?

• Strongest protection tends to be formulation and method-of-use claims that map tightly to the approved label and are difficult to design around.
• If substance protection is expired and formulation protection is weak or narrow, generic entrants usually rely on design-around or authorization-to-market strategies that limit injunction leverage.

When does BENDEKA lose exclusivity and what are the generic launch scenarios?

For a product with mature bendamustine active ingredient history, exclusivity timelines generally compress into two real-world phases:

1. Direct generic entry once all enforceable Orange Book barriers lift for each strength/pack
2. Broader share erosion even after legal barriers end as supply and contracting preferences shift

What generic launch scenarios change revenue fastest?

The revenue impact accelerates when multiple brands appear concurrently:

• Multiple ANDAs launched at launch-of-first-generic date (drives rapid price compression)
• Hospital group purchasing organization switches to lowest-cost equivalent

What does dosing form matter for substitution?

Substitution speed depends on:

• Strength availability and pack size
• Pharmacy handling complexity
• Any stability differences that affect stocking and wastage

What market dynamics drive BENDEKA sales for bendamustine in iNHL?

BENDEKA is positioned in oncology where bendamustine regimens are used at meaningful rates across community and academic centers. Market outcomes are a function of where bendamustine sits versus competing backbones and newer targeted agents.

How do competing chemoimmunotherapy and targeted combinations affect BENDEKA?

For iNHL, prescribing patterns shift when:

• New targeted combinations yield superior response durability or lower toxicity
• BTK inhibitors and other targeted therapies are adopted earlier in relapse sequences
• Clinicians prefer regimens with more predictable administration schedules or fewer dose-limiting toxicities

Where bendamustine retains share?

Bendamustine regimens tend to retain demand when:

• They deliver strong efficacy in relapsed indolent settings
• They are integrated into established pathways and provider familiarity
• Payer coverage and acquisition cost favor bendamustine-based chemotherapy over higher-cost alternatives

How does BENDEKA compare with other bendamustine brands and generics?

From a commercial standpoint, BENDEKA competes primarily against:

• Authorized generic/first wave ANDAs (fastest share impact)
• Later-wave generics (incremental price compression but often already entrenched after first entries)
• Alternative regimens that reduce reliance on bendamustine (oncology standard-of-care shifts)

What determines whether BENDEKA can hold pricing?

• Presence and number of generic competitors per strength
• Contracting structure (tender-based pricing vs. list-price reimbursement)
• Institutional prescribing habits

What is the revenue projection for BENDEKA and what are the key value drivers?

A robust revenue projection depends on current U.S. demand for bendamustine-containing regimens and the rate of share erosion from generics. Without a current BENDEKA baseline sales figure in the provided information set, only scenario logic can be stated: branded sales typically track the blend of (1) underlying bendamustine patient share and (2) branded penetration under competitive contracting.

Scenario framework for BENDEKA revenue (directional)

• Bull scenario (slower branded erosion): stable formulary position in top accounts, limited generic price undercutting in certain packs/strengths, and clinical uptake sustaining bendamustine utilization.
• Base scenario (typical mature oncology dynamics): ongoing generic pressure with partial retention of brand in specific institutions; utilization remains but branded penetration declines.
• Bear scenario (accelerated share loss): increased generic competition, deeper contracting switches, and substitution by targeted regimens that reduce bendamustine cycles per patient.

Value driver checklist (what moves quarterly revenue most)

• Generic availability and pricing per strength and pack
• Hospital group purchasing changes and reimbursement shifts
• Dose intensity changes in real-world practice (toxicity management, neutropenia support)
• Cycle mix across relapsed vs. later lines

What clinical trial outcomes could materially affect BENDEKA demand?

Material demand shocks typically require one of:

• Demonstrated superiority of bendamustine-based regimens in a high-volume line of therapy (PFS or OS improvement with manageable toxicity)
• Evidence enabling expanded use into populations currently treated with non-bendamustine regimens
• Reduced time on treatment or simpler schedule enabling outpatient infusion adoption

What patent litigation, settlements, or Paragraph IV activity affects BENDEKA?

For many mature small-molecule oncology products, Paragraph IV litigation occurs around Orange Book-listed patents at the time generic entries are imminent. The practical implication for BENDEKA is settlement-driven entry timing, typically impacting:

• The date of first commercial generic launch for a given strength
• The magnitude of early share loss (settlement terms can delay or limit entry)
• Whether “at-risk” launches occur during injunction windows

Key Takeaways

• BENDEKA’s clinical relevance is tied to bendamustine-based combination regimens, especially in indolent B-cell malignancies where bendamustine remains a commonly used backbone.
• Commercial risk is primarily structural: generic erosion and contracting dynamics usually dominate clinical evidence in determining branded sales trajectory.
• The strongest levers for BENDEKA value are (1) how quickly additional generics entered by strength and (2) whether clinical trial updates shift prescribing in a way that preserves bendamustine cycle share despite alternative targeted regimens.
• Patent enforcement for mature actives generally has diminishing impact unless formulation or tightly scoped method patents are still in force and difficult to design around.

FAQs

1. How do bendamustine combination trial results translate into BENDEKA prescribing patterns in indolent NHL?
2. What strength-specific factors (pack size, stability, handling) most influence generic substitution for BENDEKA?
3. Which endpoints most predict real-world adoption of bendamustine regimens after relapse?
4. How do hospital group purchasing and tender pricing usually change branded bendamustine share after first generic entry?
5. What Orange Book patent categories (formulation vs. method of use vs. process) most often determine whether generic entry can be enjoined?

References

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.
2. ClinicalTrials.gov. Search results for bendamustine combination studies across indolent NHL and related indications. U.S. National Library of Medicine.